Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter H Jones

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Journal of Clinical Lipidology|January 15, 2013
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studiesEli M Roth, Robert S Rosenson, Peter H Jones, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|February 9, 2010
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trialsPeter H Jones, Kenneth Cusi, Michael H Davidson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 14, 2009
CD11c expression in adipose tissue and blood and its role in diet-induced obesityHuaizhu Wu, Xiaoyuan Dai Perrard, Qun Wang, et al.
The American Journal of Cardiology|February 24, 2007
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteinsBela F Asztalos, Florence Le Maulf, Gerald E Dallal, et al.
The Journal of Clinical Endocrinology and Metabolism|November 3, 2005
Eotaxin and obesityAbu R Vasudevan, Huaizhu Wu, Antonios M Xydakis, et al.
Journal of Lipid Research|December 2, 2008
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markersThomas M van Himbergen, Nirupa R Matthan, Nancy A Resteghini, et al.
The American Journal of Cardiology|July 16, 2003
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Peter H Jones, Michael H Davidson, Evan A Stein, et al.
JAMA|September 8, 2005
Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trialMichael Fordis, Jason E King, Christie M Ballantyne, et al.
Clinical Drug Investigation|September 12, 2008
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programmePeter H Jones, Harold E Bays, Michael H Davidson, et al.
Journal of Clinical Lipidology|January 29, 2013
A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier diseaseSmita I Negi, Ariel Brautbar, Salim S Virani, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Journal of Clinical Lipidology|January 15, 2013
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studiesEli M Roth, Robert S Rosenson, Peter H Jones, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|February 9, 2010
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trialsPeter H Jones, Kenneth Cusi, Michael H Davidson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 14, 2009
CD11c expression in adipose tissue and blood and its role in diet-induced obesityHuaizhu Wu, Xiaoyuan Dai Perrard, Qun Wang, et al.
The American Journal of Cardiology|February 24, 2007
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteinsBela F Asztalos, Florence Le Maulf, Gerald E Dallal, et al.
The Journal of Clinical Endocrinology and Metabolism|November 3, 2005
Eotaxin and obesityAbu R Vasudevan, Huaizhu Wu, Antonios M Xydakis, et al.
Journal of Lipid Research|December 2, 2008
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markersThomas M van Himbergen, Nirupa R Matthan, Nancy A Resteghini, et al.
The American Journal of Cardiology|July 16, 2003
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Peter H Jones, Michael H Davidson, Evan A Stein, et al.
JAMA|September 8, 2005
Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trialMichael Fordis, Jason E King, Christie M Ballantyne, et al.
Clinical Drug Investigation|September 12, 2008
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programmePeter H Jones, Harold E Bays, Michael H Davidson, et al.
Journal of Clinical Lipidology|January 29, 2013
A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier diseaseSmita I Negi, Ariel Brautbar, Salim S Virani, et al.
Pageof 11